

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	754	(548/236).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/02/07 08:23
L2	1582	(514/374).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/02/07 08:24
L3	18	((("20040209920") or ("20040209931") or ("20040209932") or ("6221633") or ("6221897") or ("6245744") or ("6277831") or ("6342512") or ("6624185")).PN.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/02/07 08:24

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 DEC 05 CASREACT(R) - Over 10 million reactions available  
NEWS 4 DEC 14 2006 MeSH terms loaded in MEDLINE/LMEDLINE  
NEWS 5 DEC 14 2006 MeSH terms loaded for MEDLINE file segment of TOXCENTER  
NEWS 6 DEC 14 CA/CAPLUS to be enhanced with updated IPC codes  
NEWS 7 DEC 21 IPC search and display fields enhanced in CA/CAPLUS with the  
IPC reform  
NEWS 8 DEC 23 New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/  
USPAT2  
NEWS 9 JAN 13 IPC 8 searching in IFIPAT, IFIUDB, and IFICDB  
NEWS 10 JAN 13 New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to  
INPADOC  
NEWS 11 JAN 17 Pre-1988 INPI data added to MARPAT  
NEWS 12 JAN 17 IPC 8 in the WPI family of databases including WPIFV  
NEWS 13 JAN 30 Saved answer limit increased  
NEWS 14 JAN 31 Monthly current-awareness alert (SDI) frequency  
added to TULSA

NEWS EXPRESS JANUARY 03 CURRENT VERSION FOR WINDOWS IS V8.01,  
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.  
V8.0 USERS CAN OBTAIN THE UPGRADE TO V8.01 AT  
<http://download.cas.org/express/v8.0-Discover/>

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that  
specific topic.

All use of STN is subject to the provisions of the STN Customer  
agreement. Please note that this agreement limits use to scientific  
research. Use for software development or design or implementation  
of commercial gateways or other similar uses is prohibited and may  
result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 08:04:15 ON 07 FEB 2006

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 08:04:29 ON 07 FEB 2006  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 FEB 2006 HIGHEST RN 873536-40-4  
DICTIONARY FILE UPDATES: 5 FEB 2006 HIGHEST RN 873536-40-4

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

\*\*\*\*\*  
\*  
\* The CA roles and document type information have been removed from \*  
\* the IDE default display format and the ED field has been added, \*  
\* effective March 20, 2005. A new display format, IDERL, is now \*  
\* available and contains the CA role and document type information. \*  
\*  
\*\*\*\*\*


Structure search iteration limits have been increased. See HELP SLIMITS  
for details.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10789019.str



chain nodes :

6 7 8 11 12 14 15 16 17

ring nodes :

1 2 3 4 5

chain bonds :

7-11 7-12 8-12 8-14 11-17 14-15 14-16

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 7-11 7-12 8-12 8-14 11-17 14-15 14-16

G1:C,O

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 11:CLASS  
12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L1        STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1                STR




G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10789019.str



chain nodes :

6 7 8 11 12 14 15 16 17

ring nodes :

1 2 3 4 5

chain bonds :

7-11 7-12 8-12 8-14 11-17 14-15 14-16

ring bonds :

1-2 1-5 2-3 3-4 4-5

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 7-11 7-12 8-12 8-14 11-17 14-15 14-16

G1:C,O

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 11:CLASS


12:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L2        STRUCTURE UPLOADED

=> d

L2 HAS NO ANSWERS

L2                STR



G1 C,O

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 08:05:12 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 14001 TO ITERATE

14.3% PROCESSED 2000 ITERATIONS 2 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 272933 TO 287107  
PROJECTED ANSWERS: 56 TO 504

L3 2 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 08:05:16 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 281879 TO ITERATE

100.0% PROCESSED 281879 ITERATIONS 238 ANSWERS  
SEARCH TIME: 00.00.04

L4 238 SEA SSS FUL L1

=> s l4 and caplus/lc

49681526 CAPLUS/LC

L5 238 L4 AND CAPLUS/LC

=> s l2

SAMPLE SEARCH INITIATED 08:05:28 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 9828 TO ITERATE

20.4% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 190619 TO 202501  
PROJECTED ANSWERS: 0 TO 0

L6 0 SEA SSS SAM L2

=> s l2 full

FULL SEARCH INITIATED 08:05:31 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 198499 TO ITERATE

100.0% PROCESSED 198499 ITERATIONS 0 ANSWERS

SEARCH TIME: 00.00.02

L7 0 SEA SSS FUL L2

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

338.64

338.85

FILE 'CAPLUS' ENTERED AT 08:05:36 ON 07 FEB 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Feb 2006 VOL 144 ISS 7

FILE LAST UPDATED: 6 Feb 2006 (20060206/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s 15


L8 19 L5

=> d ibib abs hitstr 1-19

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2005:1262021 CAPLUS  
 DOCUMENT NUMBER: 144:22913  
 TITLE: Preparation of arylcycloalkyl oxazole derivatives and their use as pharmaceuticals  
 INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schafer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang  
 PATENT ASSIGNEE(S): Germany  
 SOURCE: U.S. Pat. Appl. Publ., 43 pp., Cont.-in-part of U.S. Ser. No. 631,867.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005267177	A1	20051201	US 2005-97345	20050404
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
US 2003144332	A1	20030731	US 2002-231432	20020830
US 6624185	B2	20030923		
US 2004122069	A1	20040624	US 2003-631867	20030801
US 6884812	B2	20050426		
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
PRIORITY APPLN. INFO.:			DE 2001-10142734	A 20010831
			DE 2002-10223273	A 20020524
			US 2002-231432	A2 20020830
			US 2003-631867	A2 20030801


GI



AB The title compds. I [ring A = (C3-C8)-cycloalkyl; R1, R2, R4, R5 = H, F, Cl, Br, OH, NO2, cyano, CF3, (C1-C6)-alkyl, O(C1-C6)-alkyl; R3 = H, (C1-C6)-alkyl; X, Y = (C1-C2)-alkyl where one C atom is replaced by O] and


L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
 (prepn. of arylcycloalkyl-oxazole derivs. for pharmaceutical use)  
 RN 501362-09-0 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[(1R,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-12-5 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-29-4 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]-2-cyclopenten-1-yl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-34-1 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
 their physiol. acceptable salts and physiol. functional derivs. are disclosed. For example, reacting cyclopent-2-ene-1,4-diol with Me 2-(bromomethyl)-6-methylbenzoate followed by hydrolysis of the ester gave benzoic acid II. The compds. typically have lipid- and/or triglyceride-lowering properties and are suitable, for example, for the treatment of disorders of lipid metab., of type II diabetes, and of syndrome X.  
 IT 710281-30-4P 710281-44-0P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)  
 RN 710281-30-4 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-44-0 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 501362-09-0P 501362-12-5P 501362-29-4P  
 501362-34-1P 501362-35-2P 501362-38-5P  
 501362-39-6P 501362-70-5P 501362-73-8P  
 710281-33-7P 710281-34-8P 710281-35-9P  
 710281-36-0P 710281-37-1P 710281-38-2P  
 710281-39-3P 710281-40-6P 710281-42-8P  
 710281-43-9P 710281-45-1P 710281-46-2P  
 710281-48-4P 710281-49-5P 710281-50-8P  
 710281-51-9P 870539-43-8P 2-[[3-[[2-(4-fluorophenyl)oxazol-4-yl]methoxy]cyclohexyl]oxy]-6-methylbenzoic acid  
 870539-53-0P 870539-58-5P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 501362-35-2 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-38-5 CAPLUS  
 CN Benzoic acid, 2-[2-[[[(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-39-6 CAPLUS  
 CN Benzoic acid, 2-[2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-70-5 CAPLUS

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-73-8 CAPLUS

CN Benzoic acid, 2-[[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 710281-33-7 CAPLUS

CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-34-8 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 710281-38-2 CAPLUS

CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 710281-39-3 CAPLUS

CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 710281-40-6 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-42-8 CAPLUS

CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 710281-35-9 CAPLUS

CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 710281-36-0 CAPLUS

CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 710281-37-1 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L8 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 710281-43-9 CAPLUS

CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 710281-45-1 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-46-2 CAPLUS

CN Benzoic acid, 2-methyl-6-[[[[(1S,3R)-3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 710281-48-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-49-5 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-50-8 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 870539-58-5 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 870539-66-5P 870539-67-6P 870539-68-7P  
870539-69-8P 870539-70-1P 870539-71-2P  
870539-72-3P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)



(Preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)  
RN 870539-66-5 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-67-6 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[4-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-51-9 CAPLUS  
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-43-8 CAPLUS  
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 870539-53-0 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[2-(trifluoromethoxy)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-68-7 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-69-8 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-methoxy-3-methylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-70-1 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-(1-methylethyl)-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-71-2 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-(1-methylethyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 870539-72-3 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[5-ethyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 501362-08-9P 501362-11-4P 501362-14-7P  
501362-19-2P 501362-44-3P 501362-69-2P  
501362-72-7P 501362-75-0P 870539-42-7P, Methyl  
2-[[3-[[2-(4-fluorophenyl)oxazol-4-yl]methoxy]cyclohexyl]oxy]-6-  
methylbenzoate 870539-51-8P 870539-55-2P  
870539-56-3P 870539-62-1P 870539-65-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)


RN 501362-08-9 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-11-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-69-2 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1S,3S)-3-[[2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-72-7 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-75-0 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 501362-14-7 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 501362-19-2 CAPLUS  
CN Benzoic acid, 5-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-2-methyl-, ethyl ester, rel-(9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 501362-44-3 CAPLUS  
CN Benzoic acid, 2-[[3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 870539-42-7 CAPLUS  
CN Benzoic acid,  
2-[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]  
]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 870539-51-8 CAPLUS  
CN Benzoic acid, 2-[[3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester, rel-(9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 870539-55-2 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-56-3 CAPLUS  
CN Benzoic acid, 2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).





RN 870539-62-1 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[1S,4R]-4-[[2-(phenyl-4-oxazolyl)methoxy]-2-cyclopenten-1-yl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-65-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[1R,3S]-3-[[5-methyl-2-[4-(1-methylethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-25-0 CAPLUS  
CN Benzoic acid, 2-[[[1-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]-3-cyclohexen-1-yl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-26-1 CAPLUS  
CN Benzoic acid, 2-[[[1-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-28-3 CAPLUS  
CN Benzoic acid, 2-[[[4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

IT 501362-06-7P 501362-20-5P 501362-21-6P  
501362-25-0P, 2-[[[1-[[2-(4-fluorophenyl)oxazol-4-yl]methoxy]methyl]cyclohex-3-enyl]methoxy]methyl]-6-methylbenzoic acid  
501362-26-1P, 2-[[[1-[[2-(4-fluorophenyl)oxazol-4-yl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methylbenzoic acid  
501362-28-3P 501362-31-8P 501362-32-9P  
501362-33-0P 501362-36-3P 501362-37-4P  
501362-45-4P 501362-46-5P 501362-47-6P  
501362-48-7P 501362-49-8P 501362-50-1P  
501362-52-3P 501362-53-4P 501362-54-5P  
501362-55-6P 501362-58-9P 501362-59-0P  
501362-60-3P 501362-61-4P 501362-62-5P  
501362-67-0P 710281-32-6P 870539-46-1P  
870539-48-3P 870539-49-4P 870539-52-5P  
870539-54-1P 870539-57-4P 870539-59-6P  
870539-63-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of arylcycloalkyl-oxazole derivs. for pharmaceutical use)


RN 501362-06-7 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[1S,3R]-3-[[2-(phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-20-5 CAPLUS  
CN Benzoic acid, 2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, ethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-21-6 CAPLUS  
CN Benzoic acid, 2-[[[1R,3R]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-31-8 CAPLUS  
CN Benzoic acid, 2-[[[1R,2R]-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclooctyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-32-9 CAPLUS  
CN Benzoic acid, 2-[[[1R,2S]-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-33-0 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-36-3 CAPLUS  
CN Benzoic acid, 2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-37-4 CAPLUS  
CN Benzoic acid, 2-[[[trans-4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-6-methyl- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 501362-45-4 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-46-5 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-52-3 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-53-4 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-54-5 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-55-6 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-47-6 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-48-7 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-49-8 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-50-1 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-58-9 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-59-0 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-60-3 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-61-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-62-5 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, (9CI) (CA INDEX NAME)




RN 501362-67-0 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-32-6 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-46-1 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 870539-54-1 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-57-4 CAPLUS  
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-59-6 CAPLUS  
CN Benzoic acid, 2-[[[(1S,3R)-3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 870539-63-2 CAPLUS




RN 870539-48-3 CAPLUS  
CN Benzoic acid, 2-[[[(1R,2R)-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 870539-49-4 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclooctyl]oxy]methyl]-6-methyl-, (9CI) (CA INDEX NAME)




RN 870539-52-9 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

CN Benzoic acid, 2-methyl-6-[[[(1S,4R)-4-[[2-phenyl-4-oxazolyl]methoxy]-2-cyclopenten-1-yl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:1132917 CAPLUS  
DOCUMENT NUMBER: 143:405613  
TITLE: Preparation of  $\alpha$ -substituted carboxylic acid as PPAR modulators  
INVENTOR(S): Bailey, Simon; Humphries, Paul Stewart; Skalitzyk, Donald J.; Su, Wei Guo; Zehnder, Luke Raymond  
PATENT ASSIGNEE(S): Agouron Pharmaceuticals, Inc., USA  
SOURCE: U.S. Pat. Appl. Publ., 150 pp.  
CODEN: USXKCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005234066	A1	20051020	US 2004-825923	20040415
US 2005187266	A1	20050825	US 2005-73274	20050304
PRIORITY APPLN. INFO.:			US 2003-463213P	P 20030415
			US 2004-825923	A2 20040415

OTHER SOURCE(S): MARPAT 143:405613  
GI


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I (Ring Q = (C6-10)aryl or 4-10 membered heterocyclyl; R1 = H, halo, alkyl, alkoxy, CN, CF3, etc.; R2 = H, (un)substituted-alkyl, -cycloalkyl, etc.; R3 = substituent of formula II, III, IV or V; R4 = -(CR11R12)n-, -(CR11R12)nS(CR11R12)n-, -(CR11R12)nNR10-, etc.; R5 = bond or -(CR11R12)mZ-(CR11R12)s, wherein Z = -(CR11R12)-, -O-, -NR10a-, or -SO-; R6 = CO2H, alkylcarbonyl, alkylester, etc.; R7 and R8 independently = H, alkyl, alkoxy, etc., or R7 and R8 taken together form a cycloalkyl or heterocyclyl; Ring A represents 3-7 membered cycloalkyl or heterocyclyl with provisions: R9 = alkyl, -(CR11R12)taryl, -(CR11R12)heterocyclyl wherein each R9 group may be substituted; R9a and R10 independently = H or alkyl; R10a = H, alkyl, etc.; R11 and R12 independently = H, alkyl, OH, alkoxy; R17 = H, CN, halo, OH, etc.; Y = CO or SO2; Y2 = NR10 or O; Ar1-4 = (un)substituted-aryl or -heteroaryl; m and s independently = 0-3; n = 0-4; p = 0-2; t = 0-5, as well as their pharmaceutically acceptable salts, are prepared Thus, e.g., VI was prepared via coupling of Me 2-((3'-hydroxybiphenyl-3-yl)oxy)-2-methylpropanoate (preparation given) with 2-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)ethanol followed by hydrolysis. In scintillation proximity assays, I possessed Ki values between 0.3 nM to 30  $\mu$ M toward PPAR. Pharmaceutical compns. containing effective ams. of I, or their salts, are useful for treating PPAR, specifically PPAR  $\alpha/\gamma$  related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.  
IT 784147-20-2P 784147-21-3P 784147-22-4P 784147-33-7P 784147-34-8P 784147-35-9P


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784147-34-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-35-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-36-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-37-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[3-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-38-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

784147-36-0P 784147-37-1P 784147-38-2P  
784147-39-3P 784147-40-6P 784147-41-7P  
784147-42-8P 784147-43-9P 784147-44-0P  
784147-45-1P 784147-46-2P 784147-47-3P  
784147-48-4P 784147-49-5P 784147-51-9P  
784147-52-0P 784147-53-1P 784147-54-2P  
784147-55-3P 784147-56-4P 784147-57-5P  
784147-58-6P 784147-59-7P 784147-60-0P  
784147-76-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate; prepn. of  $\alpha$ -substituted carboxylic acid derivs. as PPAR modulators)


RN 784147-20-2 CAPLUS  
CN Cyclohexanecarboxylic acid, 1-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-21-3 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-22-4 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-33-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784147-39-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-40-6 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-[[3-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-41-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(2-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-42-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-[[4-(aminocarbonyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-43-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-[[4-(aminocarbonyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


RN 784147-43-9 CAPIUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI)  
(CA INDEX NAME)




RN 784147-44-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-45-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-({4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl)methyl}- (9CI) (CA INDEX NAME)




RN 784147-46-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-(2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-47-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-{2-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
oxazolyl)methoxy]phenyl)methyl)-(9CI) (CA INDEX NAME)




RN 784147-54-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(2,5-diphenyl-4-oxazolyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-55-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[(2,5-diphenyl-4-oxazolyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 784147-56-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[3-(2,5-diphenyl-4-oxazolyl)propoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-57-5 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-(2-[1,1'-biphenyl]-4-yl)-5-methyl-4-oxazolyl]ethoxy]phenoxy)- (9CI) (CA INDEX NAME)




RN 784147-58-6 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-(5-methyl-2-phenyl-4-


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784147-48-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (CA  
INDEX NAME)




RN 784147-49-5 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-(2-(3-chlorophenyl)-5-methyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-51-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-52-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl)- (9CI) (CA INDEX NAME)




RN 784147-53-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[(2,5-diphenyl-4-


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
oxazolyl)ethoxylphenoxyl)- (9CI) (CA INDEX NAME)




RN 784147-59-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 784147-60-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 784147-76-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]phenyl]methyl]- (SCI) (CA INDEX NAME)




IT 784148-97-49 784148-98-59 784148-94-3P  
784148-95-49 784148-98-79 784148-99-8P  
784149-00-49 784149-02-6P 784149-03-7P  
784149-04-09 784149-05-9P 784149-06-0P  
784149-07-1P 784149-09-3P 784149-12-8P  
784149-15-1P 784149-16-2P 784149-83-3P  
784149-84-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(L)R[EMG]R[ES]R[EP] preparation of  $\alpha$ -substituted carboxylic acid derivative.

```


AS      PPAR modulators)
RN      784148-87-4  CAPLUS
CN      Cyclohexanecarboxylic acid, 1-{hydroxy[4-[2-(5-methyl-2-phenyl-4-

```


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
oxazolyl]ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 784148-88-5 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[hydroxy[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784148-94-3 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 784148-95-4 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 784148-98-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-[3-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784148-99-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(2-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-00-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(4-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-02-6 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-03-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784149-04-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-05-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-06-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-07-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 784149-09-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-12-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-15-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-16-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)






RN 784149-83-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)]propenyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-84-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)]propenyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




784147-42-8P 784147-43-9P 784147-44-0P  
784147-45-1P 784147-46-2P 784147-47-3P  
784147-48-4P 784147-49-5P 784147-51-9P  
784147-52-0P 784147-53-1P 784147-54-2P  
784147-55-3P 784147-56-4P 784147-57-5P  
784147-58-6P 784147-59-7P 784147-60-0P  
784147-76-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(drug candidate: prepn. of  $\alpha$ -substituted carboxylic acid derivs. as ppar modulators)


RN 784147-20-2 CAPLUS  
CN Cyclohexanecarboxylic acid, 1-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-21-3 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-22-4 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-33-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)]propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2005:904348 CAPLUS  
DOCUMENT NUMBER: 143:248077  
TITLE: Preparation of  $\alpha$ -substituted carboxylic acid as ppar modulators  
INVENTOR(S): Su, Wei Guo  
PATENT ASSIGNEE(S): Pfizer Inc, USA  
SOURCE: U.S. Pat. Appl. Publ., 128 pp., Cont.-in-part of U.S. Ser. No. 825,923.  
CODEN: USXXCO  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005187266	A1	20050825	US 2005-73274	20050304
US 2005234066	A1	20051020	US 2004-825923	20040415
PRIORITY APPLN. INFO.:				P 20030415
				US 2004-825923 A2 20040415

OTHER SOURCE(S): MARPAT 143:248077  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I (Ring Q = (C6-10)aryl or 4-10 membered heterocyclyl; R1 = H, halo, alkyl, alkoxy, CN, CF3, etc.; R2 = H, (un)substituted-alkyl, -cycloalkyl, etc.; R3 = substituent of formula II, III, IV or V; R4 = -(CR11R12)n-, -(CR11R12)nS(CR11R12)n-, -(CR11R12)nNR10-, etc.; R5 = bond or -(CR11R12)mZ-(CR11R12)s, wherein Z = -(CR11R12)-, -O-, -NR10a-, or -SO-; R6 = CO2H, alkylcarbonyl, alkylester, etc.; R7 and R8 independently = H, alkyl, alkoxy, etc., or R7 and R8 taken together form a cycloalkyl


or heterocyclyl; Ring A represents 3-7 membered cycloalkyl or heterocyclyl with provisions: R9 = alkyl, -(CR11R12)taryl, -(CR11R12)heterocyclyl wherein each R9 group may be substituted; R9a and R10 independently = H

or alkyl; R10a = H, alkyl, etc.; R11 and R12 independently = H, alkyl, OH, alkoxy; R17 = H, CN, halo, OH, etc.; Y = CO or SO2; Y2 = NR10 or O; Ar1-4 = (un)substituted-aryl or -heteroaryl; m and s independently = 0-3; n = 0-4; p = 0-2; t = 0-5), as well as their pharmaceutically acceptable salts, are prepared as PPAR modulators. Thus, e.g., VI (disclosed compound I)


was prepared in 47% yield via hydrolysis of its Me ester. In scintillation proximity assays, I possessed Ki values between 0.3 nM to 30  $\mu$ M toward PPAR. Pharmaceutical compns. containing effective amts. of I, or their salts,

are useful for treating PPAR, specifically PPAR  $\alpha/\gamma$  related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.


IT 784147-20-2P 784147-21-3P 784147-22-4P  
784147-33-7P 784147-34-8P 784147-35-9P  
784147-36-0P 784147-37-1P 784147-38-2P  
784147-39-3P 784147-40-6P 784147-41-7P




RN 784147-34-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)]propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-35-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)]propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-36-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)]methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-37-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-38-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-39-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)





RN 784147-40-6 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-41-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(2-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-42-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(4-aminocarbonyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-48-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-49-5 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-51-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-52-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-53-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


RN 784147-43-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(3-fluoro-4-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-44-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-45-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-46-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-47-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-54-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(2,5-diphenyl-4-oxazolyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-55-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-56-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(2,5-diphenyl-4-oxazolyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-57-5 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(1,1'-biphenyl)-4-yl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-58-6 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
oxazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-59-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-{3-(5-methyl-2-phenyl-4-oxazolyl)propoxy}phenoxy]- (9CI) (CA INDEX NAME)



RN 784147-60-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-{3-(5-methyl-2-phenyl-4-oxazolyl)methoxy}phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-76-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-{2-(2-{1,1'-biphenyl}-4-yl-5-methyl-4-oxazolyl)ethoxy}phenyl]methyl]- (9CI) (CA INDEX NAME)




IT 784148-87-4P 784148-88-5P 784148-94-3P  
784148-95-4P 784148-98-7P 784148-99-8P  
784149-00-4P 784149-02-6P 784149-03-7P  
784149-04-8P 784149-05-9P 784149-06-0P  
784149-07-1P 784149-09-3P 784149-12-8P  
784149-15-1P 784149-16-2P 784149-83-3P  
784149-84-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; preparation of  $\alpha$ -substituted carboxylic acid derivs.

as ppar modulators)  
RN 784148-87-4 CAPLUS  
CN Cyclohexanecarboxylic acid, 1-[hydroxy[4-[2-(5-methyl-2-phenyl-4-


L8 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
oxazolyl]ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 784148-88-5 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[hydroxy[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784148-94-3 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 784148-95-4 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 784148-98-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-[2-{3-(dimethylamino)phenyl}-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 784148-99-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-[2-(2-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-00-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-[2-(4-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-02-6 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-[2-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-03-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 784149-04-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-[2-(4-methylphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-05-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-06-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-07-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[4-[2-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-09-3 CAPLUS  
 CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-[3-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-12-8 CAPLUS  
 CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-15-1 CAPLUS  
 CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-16-2 CAPLUS  
 CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-83-3 CAPLUS  
 CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-84-4 CAPLUS  
 CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)





ACCESSION NUMBER: 2005:588852 CAPLUS  
 DOCUMENT NUMBER: 143:115351  
 TITLE: Preparation of 2-(phenoxymethyl)benzoic acids  
 INVENTOR(S): Fiedler, Wolfgang; Neises, Bernd; Hachtel, Jochen  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 36 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061427	A2	20050707	WO 2004-EPI4602	20041222
WO 2005061427	A3	20051006		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW  
 RW: BW, CH, GM, KE, LS, MW, NZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


DE 10360525	B3	20050818	DE 2003-10360525	20031222
US 2005171205	A1	20050804	US 2004-18038	20041221
PRIORITY APPLN. INFO.:			DE 2003-10360525	A 20031222
			US 2004-587798P	P 20040714

OTHER SOURCE(S): CASREACT 143:115351  
 GI




AB Title compds. I [R = alkyl, heterocycle, aryl, etc.; R1 = Xlm; X1 = halo,

alkyl, alkoxy, etc.; m = 0-4; R2 = (X2)m; X2 = halo, alkyl, alkoxy, etc.] were prepd via the esterification of phthalides with resorcinols, followed by O-alkylation. For example, benzylbromide O-alkylation of resorcin II (R = H) afforded 2-(phenoxymethyl)benzoic acid II (R = PhCH2) in 47% yield. Compds. I are suitable as peroxisome proliferator activated receptor (PPAR) modulators (no data provided).  
 IT 303218-47-5P 303219-55-8P  
 RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of 2-(phenoxymethyl)benzoic acids)  
 RN 303218-47-5 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl]- (9CI) (CA INDEX NAME)



RN 303219-55-8 CAPLUS  
 CN Benzoic acid, 2-[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]phenoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2005:260039 CAPLUS  
DOCUMENT NUMBER: 142:336130



TITLE: Preparation of substituted benzoic acids for treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPARs)  
INVENTOR(S): Damon, Robert Edson; Vedananda, Thalathani Ralalage  
PATENT ASSIGNEE(S): Novartis AG, Switz.; Novartis Pharma GmbH  
SOURCE: PCT Int. Appl., 85 pp.  
CODEN: PIX002

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COURT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005026134	A1	20050324	WO 2004-EP10393	20040916
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NZ, OM, PG, PH, PL, PT, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG</p>				

PRIORITY APPLN. INFO.: US 2003-503950P P 20030917

OTHER SOURCE(S): MARPAT 142:336130  
GI



AB The title compds. I [R1 = H, alkyl, (hetero)aryl, aralkyl, cycloalkyl; R2,

L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

R3 = H, halo, OH, CN, etc.; or R2 and R3 combined together with the carbon

atoms they are attached to form (un)substituted fused 5-6 membered (hetero)aryl; R4, R5 = H, halo, alkyl, alkoxy, (hetero)aralkyl; R4C and R5C may be replaced by nitrogen atom; X = Z(CH2)pQW (wherein Z = a bond, O, S, SO, CO, etc.; p = 1-8; Q = a bond, CO, O(CH2)1-8, etc.; W = cycloalkyl, aryl, heterocyclyl, etc.); AB = NHSO2, Y(R8)2 (Y = O, S; R8 = H, alkyl) which bind to Peroxisome Proliferator-Activated Receptors (PPARs), were prepd. E.g., a multi-step synthesis of II, starting from sodium 4-hydroxybenzenesulfonate dihydrate, was given. The compd. II showed an EC50 of about 8 nM in the PPARα receptor binding assay, an EC50 of about 5 nM in the PPARγ receptor binding assay, and an EC50 of about 3500 nM in the PPARδ receptor binding assay. Furthermore, the compd. II significantly lowers serum glucose and insulin levels at a daily dose of about 30 mg/kg p.o. in the ob/ob mice. The compds. I are useful for the treatment of conditions mediated by the PPAR receptor activity in mammals. Such conditions include dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis,

hypertriglyceridemia, heart failure, myocardial infarction, vascular diseases, cardiovascular diseases, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorders, respiratory diseases, ophthalmic disorders, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease. The compds. of the present invention are particularly useful in mammals as hypoglycemic agents for the treatment and prevention of conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type-1 and type-2 diabetes,

and Syndrome X. The pharmaceutical compns. comprising the compd. I and other therapeutic agents are disclosed.

IT 848569-53-9P 848569-54-0P 848569-55-1P  
848569-56-2P 848569-57-3P 848569-58-4P  
848569-59-5P 848569-60-0P 848569-61-9P  
848569-62-0P 848569-63-1P 848569-64-2P  
848569-65-3P 848569-66-4P 848569-67-5P  
848569-68-6P 848569-69-7P 848569-70-0P  
848569-71-1P 848569-72-2P 848569-73-3P  
848569-74-4P 848569-75-5P 848569-76-6P  
848569-77-7P 848569-78-8P 848569-79-9P  
848569-80-2P 848569-81-5P 848569-82-6P  
848569-93-7P 848569-94-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of substituted benzoic acids for treating conditions mediated

by Peroxisome Proliferator-Activated Receptors (PPARs))


RN 848569-53-9 CAPLUS

CN Benzoic acid, 2-methyl-6-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-4-propoxy-, methyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 848569-54-0 CAPLUS  
CN Benzoic acid, 4-methoxy-2-[[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)



RN 848569-55-1 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]-4-propoxy-, methyl ester (9CI) (CA INDEX NAME)




RN 848569-56-2 CAPLUS  
CN Benzoic acid, 4-chloro-2-[[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]-, ethyl ester (9CI) (CA INDEX NAME)




RN 848569-57-3 CAPLUS  
CN 2-Naphthalenecarboxylic acid, 3-[[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)


L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 848569-58-4 CAPLUS  
CN Benzoic acid, 2-[[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]-4-propoxy- (9CI) (CA INDEX NAME)




RN 848569-59-5 CAPLUS  
CN Benzoic acid, 4-methyl-2-[[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-60-8 CAPLUS  
CN Benzoic acid, 4-chloro-2-[[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-61-9 CAPLUS  
CN Benzoic acid, 4-chloro-2-[[4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methoxy]- (9CI) (CA INDEX NAME)




RN 848569-62-0 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]-4-propoxy- (9CI) (CA INDEX NAME)




RN 848569-63-1 CAPLUS  
CN Benzoic acid, 2-methyl-4-(1-methylethoxy)-6-[[3-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 848569-64-2 CAPLUS  
CN Benzoic acid, 2,4-dimethoxy-6-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 848569-65-3 CAPLUS  
CN Benzoic acid, 2,4-dimethoxy-6-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 848569-70-0 CAPLUS  
CN Benzoic acid, 2-methyl-4-(1-methylethoxy)-6-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 848569-71-1 CAPLUS  
CN Benzoic acid, 2-fluoro-6-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 848569-72-2 CAPLUS  
CN Benzoic acid, 2-methoxy-6-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 848569-73-3 CAPLUS  
CN Benzoic acid, 2-methoxy-6-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 848569-66-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]-4-propoxy- (9CI) (CA INDEX NAME)




RN 848569-67-5 CAPLUS  
CN Benzoic acid, 2-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]-4,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 848569-68-6 CAPLUS  
CN Benzoic acid, 2-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]-4,6-bis(trifluoromethyl)- (9CI) (CA INDEX NAME)




RN 848569-69-7 CAPLUS  
CN Benzoic acid, 2-fluoro-6-[[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 848569-74-4 CAPLUS  
CN Benzoic acid, 4-chloro-2-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 848569-75-5 CAPLUS  
CN Benzoic acid, 2-[[4-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methoxy]-6-methyl-4-(1-methylpropoxy)- (9CI) (CA INDEX NAME)




RN 848569-76-6 CAPLUS  
CN Benzoic acid, 4-fluoro-2-[[4-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methoxy]-6-(1-methylethoxy)- (9CI) (CA INDEX NAME)




RN 848569-77-7 CAPLUS


L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Benzoic acid, 4-fluoro-2-[[4-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methoxy]-6-propoxy- (9CI) (CA INDEX NAME)




RN 848569-78-8 CAPLUS  
 CN Benzoic acid, 2-[[4-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methoxy]-6-methyl-4-(1-methylethoxy)- (9CI) (CA INDEX NAME)



RN 848569-79-9 CAPLUS  
 CN Benzoic acid, 2-methyl-4-[(1-methylethoxy)-6-[[4-[2-[5-methyl-2-[(4-trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)




RN 848569-80-2 CAPLUS  
 CN Benzoic acid, 2-[[4-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]methoxy]phenyl]methoxy]-6-methyl-4-[(tetrahydro-3-furanyl)oxy]methyl]- (9CI) (CA INDEX NAME)




PAGE 1-A

L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



IT 848569-89-1P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of substituted benzoic acids for treating conditions mediated by Peroxisome Proliferator-Activated Receptors (PPARs))

RN 848569-89-1 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]-4-propoxy-, 2-propenyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT


L8 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 PAGE 1-B




RN 848569-91-5 CAPLUS  
 CN 1-Naphthalenecarboxylic acid, 2-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 848569-92-6 CAPLUS  
 CN Benzoic acid, 4-chloro-2-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 848569-93-7 CAPLUS  
 CN Benzoic acid, 4-chloro-2-[[3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]methyl]phenyl]methoxy]- (9CI) (CA INDEX NAME)



RN 848569-94-8 CAPLUS  
 CN Benzoic acid, 2-[[4-[2-[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methoxy]-6-methyl-4-[(tetrahydro-3-furanyl)oxy]- (9CI) (CA INDEX NAME)




L8 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2005:120864 CAPLUS  
 DOCUMENT NUMBER: 142:219048  
 TITLE: Preparation of diphenyl ether derivatives as PPARδ agonists  
 INVENTOR(S): Kusuda, Shinya; Nakayama, Yoshisuke; Ima, Masaki; Tajima, Hisao; Kato, Sachiko  
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 134 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005012221	A1	20050210	WO 2004-JP11424	20040803
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SI, TJ, TM, TN, TR, TT, UA, UG, US, UZ, VC, VN, YU, ZA, ZH, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZH, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPL. INFO.: JP 2003-286199 A 20030804

OTHER SOURCE(S): MARPAT 142:219048  
 GI



II

AB The title compds. I [wherein rings A, B, and D = independently (un)substituted (hetero)cycle; W = a spacer; X = a spacer; Y = a bond or a spacer; Z = a acid group], or salts, solvates, or prodrugs thereof are

L8 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
prepd. as peroxisome proliferator-activated receptors (PPAR) agonists.  
For example, the compd. II was prepd. in a multi-step synthesis. II  
increased HDL level and lowered LDL level in rat. I are useful as a  
preventive and/or therapeutic agent for diseases caused by sugar/lipid  
abnormal metab. (diabetes, hyperlipemia, arteriosclerosis, cardiovascular  
diseases, obesity, metabolic syndrome, etc.), hypertension, circulatory  
diseases, inflammatory skin diseases, etc. (no data). Formulations

contg.

I as an active ingredient were also described.

IT 840542-59-8P 840542-63-4P 840542-66-7P

840542-94-1P 840543-23-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
(Uses)

(drug candidate; preparation of di-Ph ether derivs. as PPAR5

agonists)


RN 840542-59-8 CAPLUS

CN Benzoic acid, 2-[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 840542-63-4 CAPLUS

CN Benzoic acid, 2-[3-[2-[5-methyl-2-phenyl-4-oxazolyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 840542-66-7 CAPLUS

CN Benzoic acid, 3-[3-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 840542-94-1 CAPLUS

CN Benzoic acid, 3-[2-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)

L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN

ACCESSION NUMBER: 2004:902360 CAPLUS

DOCUMENT NUMBER: 141:379637

TITLE: Preparation of  $\alpha$ -alpha substituted carboxylic acid as ppar modulators  
Bailey, Simon; Humphries, Paul Stuart; Skaltitzky,  
Donald James; Su, Wei-Guo; Zehnder, Luke Raymond  
Pfizer Inc., USA

PATENT ASSIGNEE(S): PCT Int. Appl., 177 pp.

SOURCE: CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004092145	A1	20041028	WO 2004-1B1159	20040401
WO 2004092145	C1	20050512		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
CA 2521915	AA	20041028	CA 2004-2521915	20040401
EP 1615899	A1	20060118	EP 2004-725121	20040401
R:	AT, BE, BG, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, TD, TG			
NL 1025946	A1	20041018	NL 2004-1025946	20040414
NL 1025946	C2	20050201		
PRIORITY APPL. INFO.:			US 2003-463213P	P 20030415
			WO 2004-1B1159	W 20040401

OTHER SOURCE(S):

GI MARPAT 141:379637


\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB Title compds. I [Ring Q = (C6-10)aryl or 4-10 membered heterocyclyl; R1 = H, halo, alkyl, alkoxy, CN, CF3, etc.; R2 = H, (un)substituted-alkyl, -cycloalkyl, etc.; R3 = substituent of formula II, III, IV or V; R4 = -(CR11R12)n-, -(CR11R12)nS(CR11R12)n-, -(CR11R12)nNR10-, etc.; R5 = bond or -(CR11R12)m2-(CR11R12)s, wherein Z = -(CR11R12)-, -O-, -NR10a-, or -SO-, R6 = CO2H, alkylcarbonyl, alkylester, etc.; R7 and R8 independently = H, alkyl, alkoxy, etc., or R7 and R8 taken together form a cycloalkyl

OR heterocyclyl; Ring A represents 3-7 membered cycloalkyl or heterocyclyl with provisions: R9 = alkyl, -(CR11R12)aryl, -(CR11R12)heterocyclyl wherein each R9 group may be substituted: R9a and R10 independently = H


OR

L8 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 840543-25-1 CAPLUS

CN Benzoic acid, 3-[2-[2-[5-methyl-2-[4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]phenoxy]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS

FORMAT

RECORD. ALL CITATIONS AVAILABLE IN THE RE

L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

alkyl; R10a = H, alkyl, etc.; R11 and R12 independently = H, alkyl, OH, alkoxy; R17 = H, CN, halo, OH, etc.; Y = CO or SO2; Y2 = NR10 or O; Ar1-4 = (un)substituted-aryl or -heteroaryl; m and s independently = 0-3; n = 0-4; p = 0-2; t = 0-5], as well as their pharmaceutically acceptable salts, are prepd. and disclosed as PPAR modulators. Thus, e.g., VI was prepd. via coupling of Me 2-[[3'-hydroxybiphenyl-3-yl]oxy]-2-methylpropanoate (prepn. given) with

2-(5-methyl-2-phenyl-2H-1,2,3-triazol-4-yl)ethanol followed by hydrolysis. In scintillation proximity assays,

I

possessed Ki values between 0.3 nM to 30  $\mu$ M toward PPAR. Pharmaceutical compns. contg. effective amts. of I, or their salts, are useful for treating PPAR, specifically PPAR  $\alpha/\gamma$  related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.

IT


784147-20-2P 784147-21-3P 784147-22-4P  
784147-33-7P 784147-34-8P 784147-35-9P  
784147-36-0P 784147-37-1P 784147-38-2P  
784147-39-3P 784147-40-6P 784147-41-7P  
784147-42-8P 784147-43-9P 784147-44-0P  
784147-45-1P 784147-46-2P 784147-47-3P  
784147-48-4P 784147-49-5P 784147-51-9P  
784147-52-0P 784147-53-1P 784147-54-2P  
784147-55-3P 784147-56-4P 784147-57-5P  
784147-58-6P 784147-59-7P 784147-60-0P  
784147-76-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of  $\alpha$ -substituted carboxylic acid derivs. as ppar modulators)


RN 784147-20-2 CAPLUS

CN Cyclohexanecarboxylic acid, 1-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-21-3 CAPLUS


CN Cyclopentanecarboxylic acid, 1-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-22-4 CAPLUS

CN Cyclopentanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)







RN 784147-33-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)]-1-propenyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-34-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-35-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-36-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-37-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[3-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(4-aminocarbonyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-43-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-44-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-45-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-46-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-38-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-39-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-40-6 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(3-dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-41-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(2-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-42-8 CAPLUS




RN 784147-47-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-48-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-49-5 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-51-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-52-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[[2-[[2-(5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
INDEX NAME]




RN 784147-53-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[(2,5-diphenyl-4-oxazolyl)methoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 784147-54-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(2,5-diphenyl-4-oxazolyl)propoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 784147-55-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[(2,5-diphenyl-4-oxazolyl)methoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 784147-56-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(2,5-diphenyl-4-oxazolyl)propoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-57-5 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

784149-00-4P 784149-02-6P 784149-03-7P  
784149-04-8P 784149-05-9P 784149-06-0P  
784149-07-1P 784149-09-3P 784149-12-8P  
784149-15-1P 784149-16-2P 784149-83-3P  
784149-84-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(intermediate; prepn. of  $\alpha$ -substituted carboxylic acid derivs. as ppar modulators)


RN 784148-87-4 CAPLUS  
CN Cyclohexanecarboxylic acid, 1-[(hydroxy[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 784148-88-5 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[(hydroxy[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784148-94-3 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784148-95-4 CAPLUS  
CN Cyclopentanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenyl]methyl]-, methyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
oxazolyl]ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-58-6 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-59-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propoxy]phenoxy]- (9CI) (CA INDEX NAME)



RN 784147-60-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenoxy]- (9CI) (CA INDEX NAME)




RN 784147-76-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-(2-[1,1'-biphenyl]-4-yl-5-methyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




IT 784148-87-4P 784148-88-5P 784148-94-3P  
784148-95-4P 784148-98-7P 784148-99-8P


L8 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 784148-98-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[3-(dimethylamino)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784148-99-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(2-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-00-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(4-cyanophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-02-6 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[3-fluoro-4-(trifluoromethyl)phenyl]-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-03-7 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(3,4-dichlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-04-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-05-9 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-06-0 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-16-2 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(4-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-83-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-propenyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-84-4 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)propyl]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT




RN 784149-07-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-09-3 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 784149-12-8 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 784149-15-1 CAPLUS  
CN Cyclobutanecarboxylic acid, 1-[[4-[2-[5-methyl-2-(3-methylphenyl)-4-oxazolyl]ethoxy]phenyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2004:740308 CAPLUS  
DOCUMENT NUMBER: 141:260737  
TITLE: Preparation of 4-(3-(2-phenyloxazol-4-ylmethoxy)cyclohexyloxy)butanoic acid derivatives as PPAR modulators for treating diabetes and atherosclerosis  
INVENTOR(S): Stapper, Christian; Keil, Stefanie; Glombik, Heiner; Falk, Eugen; Goerlitz, Jochen; Gretzke, Dirk; Schaefer, Hans-Ludwig; Wendler, Wolfgang  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
SOURCE: PCT Int. Appl., 163 pp.  
DOCUMENT TYPE: CODEN: PIXXD2  
LANGUAGE: Patent  
FAMILY ACC. NUM. COUNT: German  
PATENT INFORMATION: 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076428	A1	20040910	WO 2004-EP1586	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RW, SG, SH, SI, SK, SL, SM, SN, SV, SZ, TD, TH, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VE, VU, WO, XG, YU, ZA, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308355	A1	20041223	DE 2003-10308355	20030227
CA 2517386	AA	20040910	CA 2004-2517386	20040219
EP 1599455	A1	20051130	EP 2004-712503	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 200409920	A1	20041021	US 2004-789017	20040227
US 2005101637	A1	20050512	US 2004-788996	20040227
US 2005215596	A1	20050929	US 2004-788997	20040227
NO 2005004398	A	20051102	NO 2005-4398	20050922
PRIORITY APPLN. INFO.:			DE 2003-10308355	A 20030227
			US 2003-487510P	P 20030715
			WO 2004-EP1586	W 20040219

OTHER SOURCE(S): MARPAT 141:260737  
GI




II

AB Title compds. I [A = cycloalkenediyl, cycloalkenediyl, etc.; R1-2 = H, F, Cl, etc.; R3 = H, alkyl, cycloalkyl, etc.; W = CH, N, etc.; p = 0-1; X = alkanediyl, etc.; Y1 = O; Y2 = alkyl, SO1-2; n = 0-2; R4-5 = H, F, alkyl; R6 = H, alkyl, etc.; R7 = H, alk(en/yn)yl, Ph, etc.; R8 = H, alkyl] are prepared. For instance, 2-Ethyl-4-[(1R,3S)-3-(2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy)cyclohexyloxy]butanoic acid (II) is prepared in

7 steps from 1,3-cyclohexanediol and 2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole (preparation given). II has EC50 = 41 nM for the PPAR $\alpha$  receptor. I are useful for the treatment of, e.g., disorders in the metabolism of fatty acids.

IT 756495-56-4P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of  
4-(3-(2-phenyloxazol-4-ylmethoxy)cyclohexyloxy)butanoic acid  
derivs. as PPAR modulators for treating diabetes and atherosclerosis)  
RN 756495-56-4 CAPLUS  
CN Cyclopropanecarboxylic acid,  
1-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-  
4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 756496-45-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation of  
4-(3-(2-phenyloxazol-4-ylmethoxy)cyclohexyloxy)butanoic acid


ACCESSION NUMBER: 2004:740307 CAPLUS  
DOCUMENT NUMBER: 141:260736  
TITLE: Preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid derivatives and related compounds used as PPAR modulators for treating type 2 diabetes and arteriosclerosis  
INVENTOR(S): Stapper, Christian; Gertzke, Dirk; Glombik, Heiner; Falk, Eugen; Goerlitz, Jochen; Keil, Stefanie; Schaefer, Hans-Ludwig; Wendler, Wolfgang  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
SOURCE: PCT Int. Appl., 189 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076427	A1	20040910	WO 2004-EP1579	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, RW, BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308355	A1	20041223	DE 2003-10308355	20030227
CA 2517381	AA	20040910	CA 2004-2517381	20040219
EP 1599452	A1	20051130	EP 2004-712490	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004209920	A1	20041021	US 2004-789017	20040227
US 2005101637	A1	20050512	US 2004-788996	20040227
US 2005215596	A1	20050929	US 2004-788997	20040227
NO 2005004408	A	20051123	NO 2005-4408	20050922
PRIORITY APPL. INFO.:			DE 2003-10308355	A 20030227
			US 2003-487510P	P 20030715
			WO 2004-EP1579	W 20040219


OTHER SOURCE(S): MARPAT 141:260736  
GI

derivs. as PPAR modulators for treating diabetes and atherosclerosis)  
RN 756496-45-4 CAPLUS  
CN Cyclopropanecarboxylic acid,  
1-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-  
4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT




II

AB Title compds. I [X = alkanediyl, oxoalkenediyl; X1 = cycloalkenediyl, cycloalkenediyl, oxocycloalkenediyl, oxocycloalkenediyl; Y1 = (un)substituted CH2, CH2CH2; Y2 = CH2, O, S, S(O), SO2, (un)substituted NH; R = (un)substituted or annulated Ph, pyridinyl, furyl, thienyl, pyrrolyl; R1 = H, alkyl, cycloalkyl, cycloalkylalkyl, Ph, aralkyl, heteroaryl, heteroarylalkyl, fluoroalkyl; R2, R3 = H, alkyl, F, (un)substituted NH; R4 = H, alkyl, F; R5 = H, F, alkyl, alkoxy; R6 = H, alkynyl, cycloalkyl, Ph, substituted alkyl; CR4R5 = cycloalkyl; R6 = H, alkyl] were prepared for use as PPAR modulators for treating disorders of the fatty acid metabolism and disorders of glucose utilization in addition to disorders, in which insulin resistance plays a part. Thus, the title compound II was prepared in a multi-stage synthesis and had EC50 for activation of the PPAR $\alpha$  receptor of 0.07 nM.

IT 754986-25-9P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid  
derivs. and related compds. as PPAR agonists)


RN 754986-25-9 CAPLUS  
CN Cyclopentanecarboxylic acid,  
1-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 754986-24-8P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid  
 derivs. and related compds. as PPAR agonists)  
 RN 754986-24-8 CAPLUS  
 CN cyclopentanecarboxylic acid,  
 1-[[[(1R,3R)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]-, 1,1-dimethylethyl ester, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 754987-29-6P  
 RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of 3-(2-phenyloxazol-4-ylmethoxy)cyclohexylmethoxyacetic acid  
 derivs. and related compds. as PPAR agonists)  
 RN 754987-29-6 CAPLUS  
 CN cyclopentanecarboxylic acid,  
 1-[[[(1R,3R)-3-[[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


ACCESSION NUMBER: 2004:740279 CAPLUS  
 DOCUMENT NUMBER: 141:260285  
 TITLE: Method for producing the enantiomeric forms of cis-1,3-cyclohexanediol derivatives using an enzymic resolution  
 INVENTOR(S): Holla, Wolfgang; Keil, Stefanie  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: PCT Int. Appl., 91 pp.  
 CODEN: PIXX2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004076390	A1	20040910	WO 2004-EP1580	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NH, NL, NO, NZ, OM, OS, PA, PE, PG, PH, PK, PL, PT, QA, RO, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, SR, SS, SV, SY, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VU, WO, WS, XA, XB, XC, XD, XE, YU, ZA, ZB, ZI, ZJ, ZK, ZL, ZM, ZN, ZZ				
DE 10308350	A1	20040916	DE 2003-10308350	20030227
CA 2516623	AA	20040910	CA 2004-2516623	20040219
EP 1599433	A1	20051130	EP 2004-712518	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 200420931	A1	20041021	US 2004-789053	20040227
NO 2005004456	A	20050926	NO 2005-4456	20050926
PRIORITY APPL. INFO.:			DE 2003-10308350	A 20030227
			US 2003-487416P	P 20030715
			WO 2004-EP1580	W 20040219

OTHER SOURCE(S): MARPAT 141:260285  
 GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*


AB The invention relates to a method for producing chiral, non-racemic, disubstituted cis-1,3-cyclohexanediols I (R1 = R'; A = Ph, 5- to 10-membered heteroarom. (containing N, O, S), C8-14-aromatic, C3-8-cycloalkyl; R3 = H, F, Cl, Br, OH, NO2, CF3, OCF3, C1-6-alkyl, C3-8-cycloalkyl, Ph; R4, R5 = H, F, Cl, Br, OH, NO2, CF3, OCF3, OCHF2, OCF2CF3, OCF2CHF2, SCF3, OPh, C1-6-alkyl, O-(C1-6-alkyl), O-(C1-6-alkyl)-O-(C1-3-alkyl); n = 1 - 3;  
 R2 = C1-8-alkyl, optionally, one or more CH2 may be replaced with an O, CO, S, SO, SO2 and substituted with 1 - 3 substituents (F, Cl, Br, CF3, CN, NO2, NHAc, NHCOCMe3, OH, OCF3, O-(C1-6-alkyl), CO2H, CO2CH2Ph, CO2-(C1-6-alkyl), tetrazole, indole, (un)substituted thiazolidine-2,4-dione, C6-10-aryl, or, protecting group (PG) [e.g., CH2OCH2Ph, CH2Ph, CH2C6H4OMe-p, SiMe2CMe3] using an enzymic resolution of racemates. The



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT


prepn. of chiral cis-I is characterized by: (a) alkylation of (±)-cis-1,3-cyclohexanediol with R2X1 (X1 = Cl, Br, I, OSO2Me (OMs), OSO2C6H4Me-p (OTs), OSO2CF3 (OTf)) in the presence of a base and a suitable solvent; (b) stereoselective, enzymic resolu. of (±)-cis-I (R1 = H) with an acyl donor, R6Cl or (R6)2O (R6 = C(=O)-(C1-16-alkyl), C(=O)-(C2-16-alkenyl), C(=O)-(C3-16-alkynyl), C(=O)-(C3-16-cycloalkyl), optionally one or more CH2 may be replaced with O substituted with 1 - 3 substituents (F, Cl, Br, CF3, CN, NO2, OH, OMe, OEt, Ph, CO2-(C1-4-alkyl), CO2-(C2-4-alkenyl))), in an org. solvent contg. an enzyme; (c) chem. hydrolysis of chiral cis-I (R1 = R6); (d) alkylation of chiral cis-I (R1 = H) with oxazole II (X2 = Cl, Br, I, OTs, OMs, OTf) in the presence of a base and a suitable solvent. Alternatively chiral cis-I is prepd. by: (a) alkylation of (±)-cis-1,3-cyclohexanediol with PG-X1 (X1 = Cl, Br, I, OMs, OTs, OTf) in the presence of a base and a suitable solvent; (b) stereoselective, enzymic resolu. of (±)-cis-I (R1 = H, R2 = PG) with an acyl donor, R6Cl or (R6)2O, in an org. solvent contg. an enzyme; (c) chem. hydrolysis of chiral cis-I (R1 = R6, R2 = PG); (d) alkylation of chiral cis-I (R1 = H; R2 = PG) with oxazole II (X2 = Cl, Br, I, OTs, OMs, OTf) in the presence of a base and a suitable solvent (e) deprotecting chiral cis-I (R2 = PG); (f) alkylation of chiral cis-I (R2 = H) with R2X1 in the presence of a base and a suitable solvent. Thus, cyclohexanediol deriv. II was prepd. from (±)-cis-1,3-cyclohexanediol via alkylation with Me 2-(bromomethyl)-6-methylbenzoate in NMP contg. KOtBu, enzymic resolu. with vinyl acetate in CH2Cl2 contg. Novozym 435, alkylation of the resulting chiral (benzyloxy)cyclohexanol III with (iodomethyl)oxazole IV, and sapon. with NaOH in EtOH.  
 IT 501362-77-2P 710281-33-7P 710281-37-1P 710281-48-4P 755030-33-2P 755030-34-3P  
 RL: BPN (Biosynthetic preparation); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)  
 (prepn. of the enantiomeric forms of cis-1,3-cyclohexanediol deriva. using an enzymic resolution)  
 RN 501362-77-2 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-33-7 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-37-1 CAPLUS  
CN Benzoic acid, 2-methyl-6-(((1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl)oxy)methyl)- (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**



RN 710281-48-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

### Absolute stereochemistry.




```

RN      755030-33-2  CAPLUS
CN      Benzoic acid, 2-[[[(1S,3R)-3-[[2-(3-methoxyphenyl)-5-methyl-4-
(CA     oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl-, methyl ester (9CI)
INDEX NAME)

```


**Absolute stereochemistry.**

ANSWER 10 OF 19 CAP  
Absolute stereochemistry.




RN 755030-27-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

**Absolute stereochemistry.**




REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE  
FORMAT




RN	755030-34-3	CAPLUS
CN	Benzoic acid, 2-([[(1S,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy)methyl]-6-methyl-, methyl ester (9CI)	
CA	INDEX NAME)	

**Absolute stereochemistry.**



IT	755030-19-4P 755030-23-0P 755030-27-4P RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent) [preparation and saponification of: prepn of the enantiomeric forms of cis-1,3-cyclohexanediol derivs. using an enzymic resolution]
RN	755030-19-4 CAPLUS
CN	Benzolic acid, 2-[[[1,1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)
(CA	INDEX NAME)

**Absolute stereochemistry.**





RN 755030-23-0 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[1R,3S)-3-[[5-methyl-2-(4-methylphenyl)-4-oxazoly]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2004:740160 CAPLUS  
DOCUMENT NUMBER: 141:260735  
TITLE: Production method for 1,3-substituted cycloalkyl derivatives containing acidic, mainly heterocyclic groups and use thereof as medicaments  
INVENTOR(S): Goerlitzer, Jochen; Glombik, Heiner; Falk, Eugen; Gretzke, Dirk; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang  
PATENT ASSIGNEE(S): Aventis Pharma Deutschland G.m.b.H., Germany  
SOURCE: PCT Int. Appl., 108 pp.  
CODEN: PIXX2  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 2  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075891	AI	20040910	WO 2004-EP1582	20040219
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NG, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RE, RO, RU, SE, SI, SK, SR, ST, SV, SW, SY, TD, TH, TJ, TM, TR, TT, UA, UG, UZ, VC, VE, VN, YU, ZA, ZM, ZW, ZY, AA, AB, AC, AD, AE, AF, AG, AH, AI, AJ, AK, AL, AM, AN, AO, AP, AQ, AR, AS, AT, AU, AV, AW, AX, AY, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MM, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NN, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RR, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TT, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ	AA	20041125	DE 2003-10308351	20030227
CA 2517307	AA	20040910	CA 2004-2517307	20040219
EP 1599203	AI	20051130	EP 2004-712489	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	AI	20041021	US 2004-789281	20040227
US 2004029932	AI	20041021	DE 2003-10308351	A 20030227
PRIORITY APPL. INFO.:			US 2003-487566P	P 20030715
			WO 2004-EP1582	W 20040219

OTHER SOURCE(S): MARPAT 141:260735  
GI



AB The invention relates to 1,3-substituted cycloalkyl derivs. containing acidic, mainly heterocyclic groups, in addition to their physiol. compatible salts and physiol. functional derivs. The invention relates to compds. I [A = C3-8-cycloalkanedyl, C3-8-cycloalkenedyl (optionally containing an O instead of one C); E = (CH2)m; R1, R2 = H, F, Br, Cl, SF5, S-(C1-6-alkyl), CF3, OCF3, C1-6-alkyl, O-(C1-6-alkyl), SCF3, OPh, OCF2CHF2, OCF2CF3, (C1-6-alkyl)-(C1-6-alkoxy), O-(C1-6-alkyl)-(C1-6-alkoxy), OCH2Ph; R3 = H, CF3, C1-6-alkyl, C3-8-cycloalkyl, Ph; X = C1-6-alkanedyl (optionally containing an O instead of C); Y = S, O, bond; m = 1 - 3; n = 0, 1; Z = O, S, C=O, C(O)NH; R = H, OH, CH2CONHOH, CH2CONH(C1-6-alkyl), CH2CONH(C1-6-alkoxy), NR4R5, 5- to 12-membered mono- or bicyclic, (un)saturated ring containing 1 or more N, O, S; R4 = H, C1-6-alkyl (optionally substituted with F, Cl, Br, CN, SH, CO2H, C1-4-alkyl, C1-6-alkoxy, SO2-(C1-4-alkyl), NO2, CF3, OCF3, (C1-6-alkyl)-(C1-6-alkoxy), (C1-6-alkoxy)-(C1-6-alkoxy), (C1-6-alkoxy)-(C1-6-alkoxy)C6H4, OPh, NHO2CF3, B(OH)2; R5 = OH, NH2, SO2CF3, SO2C6H4CF3, COCF3, C1-6-alkoxy, Ph, C6H4Me, C6H4CO2H; NR4R5 = (un)substituted 5-membered aromatic heterocycle, optionally fused with 5- to 7-membered aromatic heterocycle (optionally substituted with F, Cl, Br, CF3, OCF3, CO2H, SO2Me, CN, C1-4-alkoxy, C1-4-alkyl, (C1-4-alkyl)C6H4, (C1-6-alkyl)-(C1-6-alkoxy), (C1-6-alkoxy)-(C1-6-alkoxy), (C1-6-alkoxy)-(C1-6-alkoxy)C6H4, OPh]], in addition to their physiol. compatible salts and to a method for their production

The compds. are suitable for treating and/or preventing disorders of the fatty acid metabolism and disorders of glucose utilization in addition to disorders, in which insulin resistance plays a part.

IT RL: BPN (Biosynthetic preparation); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)


(preparation and saponification of; preparation of 1,3-substituted cycloalkane

heterocyclic derivs. for use in treating metabolic disorders)

RN 753459-78-8 CAPLUS

CN Benzoic acid, 2-methyl-6-[2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]ethoxy]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 753459-40-4P 753459-41-5P 753459-42-6P

753459-44-6P 753459-45-6P 753459-46-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 1,3-substituted cycloalkane heterocyclic derivs. for use in treating metabolic disorders)

RN 753459-40-4 CAPLUS

CN Benzoic acid, 2-methyl-6-[2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-41-5 CAPLUS

CN Benzoic acid, 2-[2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-42-6 CAPLUS

CN Benzoic acid, 2-fluoro-6-[2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-44-8 CAPLUS

CN Benzoic acid, 4-methoxy-2-[2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]ethoxy]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-45-9 CAPLUS

CN Benzoic acid, 2-methyl-6-[2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]ethoxy]-4-(2-methylpropoxy)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 753459-46-0 CAPLUS

CN Benzoic acid, 2-methyl-6-[2-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]ethoxy]-4-(phenylmethoxy)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

ACCESSION NUMBER: 2004:740108 CAPLUS  
 DOCUMENT NUMBER: 141:260734  
 TITLE: Preparation of diarylcycloalkyl oxazole derivatives and their use in the treatment of, e.g., fatty acid metabolism  
 INVENTOR(S): Goerlitz, Jochen; Glombik, Heiner; Falk, Eugen; Grotzke, Dirk; Keil, Stefanie; Schaefer, Hans-Ludwig; Stapper, Christian; Wendler, Wolfgang  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: PCT Int. Appl., 61 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004075815	A2	20040910	WO 2004-EP1584	20040219
WO 2004075815	A3	20041229		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NG, NO, NZ, OM, PA, PE, PG, PH, PK, PL, PT, RO, RU, RW, SA, SC, SD, SE, SG, SI, SK, SL, SM, SN, SR, SS, SV, SY, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VE, VJ, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MM, MW, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10308353	A1	20041202	DE 2003-10308353	20030227
CA 2516573	AA	20040910	CA 2004-2516573	20040219
EP 1599454	A2	20051130	EP 2004-712502	20040219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2004204462	A1	20041014	US 2004-789019	20040227
NO 2005004381	A	20050921	NO 2005-4381	20050921
NO 2005004382	A	20050921	NO 2005-4382	20050921
PRIORITY APPLN. INFO.:			DE 2003-10308353	A 20030227
			DE 2003-10308351	A 20030227
			US 2003-494911P	P 20030813
			WO 2004-EP1584	W 20040219


OTHER SOURCE(S): MARPAT 141:260734  
 GI



AB Title compds. I [A = cycloalkenediyl, cycloalkenediyl, etc.; B = Ph, heterocyclic, etc.; R1 = SCF3, OCF2-CHF2, phenoxy, etc.; R2 = H, CF3; R3 = H, alkyl; R4 = Ph, H, F, Cl, Br, etc.; R5 = H, F, Cl, Br, OH, etc.; X, Y = alkanediyl, etc.] are prepared For instance, 2-Methyl-6-(((1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]benzoic acid (II) is prepared in 7 steps using naphthalene-2-carboxaldehyde, diacetylmonooxime, 1,3-cyclohexanediol and 2-bromomethyl-6-methylbenzoic acid Me ester. II has an EC50 = 0.2 nM for the PPARα receptor. I are useful for treating disorders of the fatty acid metabolism and glucose utilization in addition to disorders of insulin resistance.

IT 755016-26-3P, 2-(((1R,3S)-3-((2-(3-fluoro-5-(trifluoromethyl)phenyl)-5-methyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid methyl ester  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (Preparation of diarylcycloalkyl oxazole derivs. and their use in treatment of, e.g., fatty acid metabolism)  
 RN 755016-26-3 CAPLUS  
 CN Benzoic acid, 2-(((1R,3S)-3-[[2-(3-fluoro-5-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl)oxy)methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 755016-12-7P, 2-Methyl-6-(((1R,3S)-3-((5-methyl-2-(naphthalen-2-yl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]benzoic acid  
 755016-20-7P, 2-(((1R,3S)-3-((5-Methyl-2-(4-((trifluoromethyl)sulfonyl)phenyl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid 755016-23-0P, 2-(((1R,3S)-3-((5-Methyl-2-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid  
 755016-24-1P, 2-(((1R,3S)-3-((5-Methyl-2-(4-phenoxyphenyl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid  
 755016-27-4P, 2-(((1R,3S)-3-((2-(3-(2-Methoxyethoxy)-5-(trifluoromethyl)phenyl)-5-methyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid 755016-28-5P, 2-Methyl-6-(((1R,3S)-3-((5-phenyl-2-(4-tolyl)oxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]benzoic acid  
 755016-30-9P, 2-(((1R,3S)-3-((2-(3-Methoxyphenyl)-5-phenyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid  
 755016-32-1P, 2-(((1R,3S)-3-((2-Cyclohexyloxazol-4-yl)methoxy)cyclohexyl)oxy)methyl]-6-methylbenzoic acid  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (Preparation of diarylcycloalkyl oxazole derivs. and their use in treatment of, e.g., fatty acid metabolism)


RN 755016-12-7 CAPLUS  
 CN Benzoic acid, 2-methyl-6-(((1R,3S)-3-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]cyclohexyl)oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755016-20-7 CAPLUS  
 CN Benzoic acid, 2-methyl-6-(((1R,3S)-3-[[5-methyl-2-(4-((trifluoromethyl)thio)phenyl)-4-oxazolyl]methoxy]cyclohexyl)oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 755016-23-0 CAPLUS  
 CN Benzoic acid, 2-methyl-6-(((1R,3S)-3-[[5-methyl-2-(3-(1,1,2,2-tetrafluoroethoxy)phenyl)-4-oxazolyl]methoxy]cyclohexyl)oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-24-1 CAPLUS  
 CN Benzoic acid, 2-methyl-6-(((1R,3S)-3-[[5-methyl-2-(4-phenoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl)oxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 755016-27-4 CAPLUS  
 CN Benzoic acid, 2-(((1R,3S)-3-[[2-(3-(2-methoxyethoxy)-5-(trifluoromethyl)phenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl)oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.






RN 755016-28-5 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[2-(4-methylphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-30-9 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 755016-32-1 CAPLUS  
CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(cyclohexyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


ACCESSION NUMBER: 2004:701970 CAPLUS  
DOCUMENT NUMBER: 141:225511  
TITLE: Preparation of substituted azoles as protein tyrosine phosphatase inhibitors for treatment of diabetes and other PTPase mediated conditions  
INVENTOR(S): Mjallil, Adnan H. M.; Andrews, Robert C.; Yarragunta, Ravindra R.; Xie, Rongyuan; Ren, Tan; Subramanian, Govindan; Quada, James C., Jr.  
PATENT ASSIGNEE(S): Transtech Pharma Inc., USA  
SOURCE: PCT Int. Appl., 224 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071448	A2	20040826	WO 2004-US4076	20040212
WO 2004071448	A3	20041014		

W: AE, AE, AG, AL, AL, AM, AM, AM, AT, AT, AU, AZ, AZ, BA, BB, BG, BG, BR, BR, BW, BY, BZ, BZ, CA, CH, CN, CN, CO, CO, CR, CR, CU, CU, CZ, CZ, DE, DE, DK, DK, DM, DE, EC, EC, EE, EE, EG, ES, ES, FI, FI, GB, GD, GE, GE, GH, GM, HR, HR, HU, HU, ID, IL, IN, IS, JP, JP, KE, KE, KG, KG, KP, KP, KR, KR, KZ, KZ, KZ, LC, LC, LR, LR, LS, LS, LT, LU, LV, NA, MD, MD, MG, MK, MN, MW, MX, MX, NZ, NZ, NA, NI  
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2004186151 A1 20040923 US 2004-777471 20040212  
PRIORITY APPLM. INFO.: US 2003-446924P P 20030212




OTHER SOURCE(S): MARPAT 141:225511  
GI



IT 755016-11-6P, 2-Methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(naphthalen-2-yl)oxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]benzoic acid methyl ester  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(Preparation of diarylcycloalkyl oxazole derivs. and their use in treatment of, e.g., fatty acid metabolism)

RN 755016-11-6 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(2-naphthalenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB Title imidazoles and analogs I (wherein m, n = independently 0, 1; A = H, alkyl, alkenyl, alkynyl; L1 = a bond, O, alkylene, CO, NHCO, NH, NHSO2, etc.; T = H, (un)substituted (cyclo)alkyl, heterocyclyl, (hetero)aryl, etc.; W = O, S, NR4; X = a bond, CO, CH2, SO2; R1 = H, halo, CN, alkyl, (hetero)aryl, heterocyclyl, etc.; R2 = H, perfluoroalkyl, alkylene optionally interrupted by one or more heteroatoms, (hetero)aryl, heterocyclyl, etc.; R3 = H, alkyl, (cyclo)alkylalkylene, (hetero)aryl(alkylene); R4 = H, alkyl, (hetero)aryl(alkyl), heterocyclyl(alkyl), etc.; Ar1 = (un)substituted optionally fused (hetero)aryl; Ar2 = (un)substituted optionally fused (hetero)arylene; and pharmaceutically acceptable salts, solvates, and prodrugs thereof) were prepared as inhibitors of protein tyrosine phosphatases (PTPases). For example, 3-[(tert-butoxycarbonyl)amino]-2-(4-butoxy-3-butoxycarbonylphenyl)-2-ethyl-4-(4-nitrophenyl)imidazole was coupled with ammonium acetate in glacial acetic acid/anhydrous DMF to afford the imidazole

II (40%). Comps. of the invention inhibited PTP 1B activity with IC50 values ranging from about 0.01  $\mu$ M to about 20  $\mu$ M. Thus, I and pharmaceutical comps. comprising them may be useful for the management, treatment, control, and adjunct treatment of diseases mediated by PTPase activity, such as Type I diabetes, Type II diabetes, immune dysfunction, AIDS, autoimmune diseases, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis and/or production of growth hormone

or cytokines, of Alzheimer's disease (no data).  
IT 745833-78-7P 745833-81-2P, 4-[[4-[(2S)-2-(4-(2,4-dichlorophenyl)oxazol-2-yl)-2-[[2-(4-methoxyphenyl)acetyl]amino]ethyl]-2-nitrophenoxymethyl]benzoic acid  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(PTPase inhibitor: preparation of substituted imidazoles as PTPase inhibitors for treatment of diabetes and other PTPase mediated conditions)


L8 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 RN 745833-78-7 CAPLUS  
 CN Benzoic acid, 4-[[[2-amino-4-[(2S)-2-[[4-(2,4-dichlorophenyl)-2-oxazolyl]-2-[[[cis-4-ethylcyclohexyl]carbonyl]amino]ethyl]phenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 745833-81-2 CAPLUS  
 CN Benzoic acid, 4-[[[4-[(2S)-2-[[4-(2,4-dichlorophenyl)-2-oxazolyl]-2-[[[4-methoxyphenyl]acetyl]amino]ethyl]-2-nitrophenoxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN  
 ACCESSION NUMBER: 2004:51338 CAPLUS  
 DOCUMENT NUMBER: 141:71532  
 TITLE: Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators  
 INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefanie; Schafer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S. Ser. No. 231,432.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004122069	A1	20040624	US 2003-631867	20030801
US 6884812	B2	20050426		
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
US 2003144332	A1	20030731	US 2002-231432	20020830
US 6624185	B2	20030923		
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
US 2005267177	A1	20051201	US 2005-97345	20050404
PRIORITY APPLN. INFO.:			DE 2001-10142734	A 20010831
			DE 2002-10223273	A 20020524
			US 2002-231432	A2 20020830
			US 2003-631867	A2 20030801

OTHER SOURCE(S): MARPAT 141:71532  
 GI

L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



AB Title oxazoles I [Z = cycloalkyl; R1, R2, R4, R5 = H, F, Cl, Br, etc.; R3 = H, Me; X, Y = alkyl (chains may contain 1 or more oxygens)] are prepared

Thus, (+)-cis-oxazole II was prepared from cyclohexane-1,3-diol via O-alkylation with 4-(iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally


alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes

and syndrome X. The bioactivity of II was determined [EC50 = 0.3 nM vs. PPAR $\alpha$ ].

IT 710281-44-0P, 2-[[[(1R,3S)-3-[[2-(3-bromophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic acid  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)

RN 710281-44-0 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 710281-30-4P, Methyl 2-[[[(1R,3S)-3-[[2-(3-Fluorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoate  
 710281-32-6P, 2-[[[(1R,3S)-3-[[2-(3-Fluorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-33-7P, 2-[[[(1R,3S)-3-[[2-(3-Methoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-34-8P, 2-[[[(1R,3S)-3-[[2-(3-Trifluoromethylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-37-1P, 2-[[[(1R,3S)-3-[[2-(3-Methylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-35-9P, 2-[[[(1R,3S)-3-[[2-(3-Chlorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-36-0P, 2-[[[(1R,3S)-3-[[2-(4-Chlorophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-37-1P, 2-[[[(1R,3S)-3-[[2-(3-Methylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-38-2P, 2-[[[(1R,3S)-3-[[2-(3,4-Dimethylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-39-3P, 2-[[[(1R,3S)-3-[[2-(2,4-Dimethylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-40-6P, 2-[[[(1R,3S)-3-[[2-(2-Methylphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-41-7P, 2-[[[(1R,3S)-3-[[2-(3-Trifluoromethoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-42-8P, 2-[[[(1R,3S)-3-[[2-(3,4-Dimethoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-43-9P, 2-[[[(1R,3S)-3-[[2-(3-Cyanophenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid  
 710281-45-1P, 2-Methyl-6-[[[(1R,3S)-3-[[5-methyl-2-phenyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]benzoic Acid 710281-46-2P, 2-Methyl-6-[[[(1S,3R)-3-[[5-methyl-2-phenyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]benzoic Acid 710281-48-4P, 2-Methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]benzoic Acid 710281-49-5P, 2-Methyl-6-[[[(1S,3R)-3-[[5-methyl-2-(p-tolyl)oxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]benzoic Acid 710281-50-8P, 2-[[[(1R,3S)-3-[[2-(4-Methoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid 710281-51-9P, 2-[[[(1S,3R)-3-[[2-(4-Methoxyphenyl)-5-methyloxazol-4-yl]methoxy]cyclohexyl]oxy]methyl]-6-methylbenzoic Acid 710281-56-4P, 2-Methyl-6-[[[(1S,4R)-4-[[5-methyl-2-phenyloxazol-4-yl]methoxy]cyclopent-2-enyl]oxy]methyl]benzoic Acid.  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)


RN 710281-30-4 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-32-6 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 710281-33-7 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-34-8 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-(trifluoromethyl)phenyl]-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-39-3 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 710281-40-6 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-41-7 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-(trifluoromethoxy)phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 710281-35-9 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-36-0 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-37-1 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-38-2 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-42-8 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-43-9 CAPLUS  
 CN Benzoic acid, 2-[[[(1R,3S)-3-[[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-45-1 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[(1R,3S)-3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-46-2 CAPLUS  
CN Benzoic acid, 2-methyl-6-([[(1S,3R)-3-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-48-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-([[(1R,3S)-3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-49-5 CAPLUS  
CN Benzoic acid, 2-methyl-6-([[(1S,3R)-3-[(5-methyl-2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



Absolute stereochemistry.



IT 501362-02-3P 501362-03-4P 501362-06-7P  
501362-09-0P 501362-12-5P 501362-15-8P  
501362-16-9P 501362-21-6P 501362-25-0P  
501362-26-1P 501362-27-2P 501362-28-3P  
501362-29-4P 501362-30-7P 501362-31-8P  
501362-32-9P 501362-33-0P 501362-34-1P  
501362-35-2P 501362-36-3P 501362-37-4P  
501362-38-5P 501362-39-6P 501362-43-2P  
501362-45-4P 501362-46-5P 501362-47-6P  
501362-48-7P 501362-49-8P 501362-50-1P  
501362-52-3P 501362-53-4P 501362-54-5P  
501362-55-6P 501362-58-9P 501362-59-0P  
501362-60-3P 501362-61-4P 501362-62-5P  
501362-65-8P 501362-67-0P 501362-70-5P  
501362-73-8P  
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and PPAR activating activity of; preparation of oxazole diacyl cycloalkyl derivs. and the use thereof as PPAR activators)  
RN 501362-02-3 CAPLUS  
CN Benzoic acid, 2-([[(3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-03-4 CAPLUS  
CN Benzoic acid, 2-([[(3-[(2-(4-methoxyphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 710281-50-8 CAPLUS  
CN Benzoic acid, 2-([[(1R,3S)-3-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-51-9 CAPLUS  
CN Benzoic acid, 2-([[(1S,3R)-3-[(2-(4-methoxyphenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 710281-56-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-([[(1S,4R)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-2-cyclopenten-1-yl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 710281-55-3P, Methyl 2-methyl-6-([[(1S,4R)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]cyclopent-2-enyl]oxy)methyl]benzoate  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(method for producing diaryl cycloalkyl derivs. of oxazole and the use thereof as PPAR activators)

RN 710281-55-3 CAPLUS  
CN Benzoic acid, 2-methyl-6-([[(1S,4R)-4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]-2-cyclopenten-1-yl]oxy)methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 501362-06-7 CAPLUS  
CN Benzoic acid, 2-methyl-6-([[(1S,3R)-3-[(2-phenyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-09-0 CAPLUS  
CN Benzoic acid, 2-methyl-6-([[(1S,3R)-3-[(2-(4-methylphenyl)-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-12-5 CAPLUS  
CN Benzoic acid, 2-([[(1R,3S)-3-[(2-(4-fluorophenyl)-5-methyl-4-oxazolyl)methoxy]cyclohexyl]oxy)methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Benzoic acid, 5-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-16-9 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-21-6 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 501362-25-0 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,2S)-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]-3-cyclohexen-1-yl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 501362-28-3 CAPLUS  
 CN Benzoic acid, 2-[[[4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxymethyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-29-4 CAPLUS  
 CN Benzoic acid, 2-[[[4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclopenten-1-yl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-30-7 CAPLUS  
 CN Benzoic acid, 2-[[[5-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclooctyl]oxymethyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-31-8 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,2R)-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclooctyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501362-26-1 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,2R)-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-27-2 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[[(1R,2R)-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501362-32-9 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,2S)-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-33-0 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,2S)-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)




RN 501362-34-1 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-35-2 CAPLUS  
 CN Benzoic acid, 2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-36-3 CAPLUS  
 CN Benzoic acid, 2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-37-4 CAPLUS  
 CN Benzoic acid, 2-[[[trans-4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-38-5 CAPLUS  
 CN Benzoic acid, 2-[[[1R,3R]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-39-6 CAPLUS  
 CN Benzoic acid, 2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-43-2 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-45-4 CAPLUS


L8 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
 CN Benzoic acid, 2-[[[3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-46-5 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-47-6 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-48-7 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-49-8 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-50-1 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-52-3 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-53-4 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-54-5 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-55-6 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-58-9 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-59-0 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-60-3 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-70-5 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-73-8 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 501362-01-2P 501362-08-9P 501362-11-4P  
 501362-14-7P 501362-19-2P 501362-20-5P  
 501362-42-1P 501362-69-2P 501362-72-7P  
 501362-75-0P 501362-77-2P  
 RL: RCT (Reactant); SPN (Synthetic Preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation and saponification of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)  
 RN 501362-01-2 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 501362-61-4 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-62-5 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-65-8 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-67-0 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-08-9 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-11-4 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-14-7 CAPLUS  
 CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-19-2 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, ethyl ester, rel- (9CI)  
 (CA INDEX NAME)

Relative stereochemistry.




RN 501362-20-5 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, ethyl ester, rel- (9CI)  
 (CA INDEX NAME)

Relative stereochemistry.




RN 501362-42-1 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)  
 (CA INDEX NAME)




RN 501362-77-2 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




IT 501362-44-3P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation, cyanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-44-3 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)  
 (CA INDEX NAME)




IT 501362-64-7P 501362-78-3P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation, methanolysis and PPAR activating activity of; preparation of oxazole diaryl cycloalkyl derivs. and the use thereof as PPAR activators)

RN 501362-64-7 CAPLUS  
 CN Benzoic acid, 2-[[[[(1S,3R)-3-[[2-(4-fluorophenyl)-4-




RN 501362-69-2 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-72-7 CAPLUS  
 CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-75-0 CAPLUS  
 CN Benzoic acid, 2-[[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-78-3 CAPLUS  
 CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




REFERENCE COUNT: 65 THERE ARE 65 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT



L8 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2004:453192 CAPLUS  
 DOCUMENT NUMBER: 141:6919  
 TITLE: Preparation of substituted aralkyl derivatives as antidiabetic, hypolipidemic and hypocholesterolemic agents  
 INVENTOR(S): Lohray, Braj Bhushan; Lohray, Vidya Bhushan; Jain, Mukul R.; Basu, Sujay; Pingali, Harikishore; Raval, Saurin K.; Raval, Preeti S.  
 PATENT ASSIGNEE(S): Cadila Healthcare Limited, India  
 SOURCE: PCT Int. Appl., 114 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004046119	A1	20040603	WO 2003-IN358	20031114
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2506112	AA	20040603	CA 2003-2506112	20031114
EP 1569916	A1	20050907	EP 2003-808341	20031114
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003015713	A	20050913	BR 2003-15713	20031114
NO 2005002413	A	20050726	NO 2005-2413	20050513
PRIORITY APPLN. INFO.:			IN 2002-MU992	A 20021115
			IN 2003-MU792	A 20030812
			WO 2003-IN358	W 20031114

OTHER SOURCE(S): MARPAT 141:6919  
 GI




AB The present invention relates to novel substituted aralkyl derivs. of formula A(CH<sub>2</sub>)<sub>n</sub>-Ar-CH<sub>2</sub>CH(R)CHR<sub>1</sub>R<sub>2</sub> [A = (substituted) aryl, heteroaryl,

L8 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




L8 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)  
 heterocyclyl; n = 1-3; X = O, S; Ar = arom., heteroatom, or heterocyclic group; R, R<sub>1</sub> = (substituted) amino, (substituted) OH, N<sub>3</sub>, CN, COOH, tetrazolyl, etc.; R<sub>2</sub> = H, alkyl, cycloalkyl, their derivs., their analogs, their tautomeric forms, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates, pharmaceutical compns. contg. them, use of these compds. in medicine and the intermediates involved in their prepn. The compds. are useful as antidiabetic, hypolipidemic and hypocholesterolemic agents. Thus, 1 was prepd., and lowered serum triglyceride in Swiss albino mice by 78%.  
 IT 696662-51-0P 696662-69-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of aralkyl derivs. as antidiabetic, hypolipidemic and hypocholesterolemic agents)  
 RN 696662-51-8 CAPLUS  
 CN Benzoic acid, 2-[(2S)-2-ethoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 696662-69-8 CAPLUS  
 CN Benzoic acid, 2-[(2S)-2-ethoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)methoxy]phenyl]propoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





IT 696663-42-0P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
 (preparation of aralkyl derivs. as antidiabetic, hypolipidemic and hypocholesterolemic agents)  
 RN 696663-42-0 CAPLUS  
 CN Benzoic acid, 2-[(2S)-2-ethoxy-3-[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]propoxy]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L8 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS ON STN  
 ACCESSION NUMBER: 2003:202470 CAPLUS  
 DOCUMENT NUMBER: 138:238169  
 TITLE: Method for producing diaryl cycloalkyl derivatives of oxazole and the use thereof as PPAR activators  
 INVENTOR(S): Glombik, Heiner; Falk, Eugen; Frick, Wendelin; Keil, Stefan; Schaefer, Hans-Ludwig; Schwink, Lothar; Wendler, Wolfgang  
 PATENT ASSIGNEE(S): Aventis Pharma Deutschland GmbH, Germany  
 SOURCE: PCT Int. Appl., 83 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003020269	A1	20030313	WO 2002-EP9221	20020817
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10142734	A1	20030327	DE 2001-10142734	20010831
DE 10223273	A1	20031204	DE 2002-10223273	20020524
CA 2458210	AA	20030313	CA 2002-2458210	20020817
EE 200400059	A	20040415	EE 2004-59	20020817
EP 1425014	A1	20040609	EP 2002-797589	20020817
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002012158	A	20040713	BR 2002-12158	20020817
CN 1549713	A	20041124	CN 2002-817085	20020817
JP 2005525294	T2	20050825	JP 2003-524576	20020817
NZ 531440	A	20051028	NZ 2002-531440	20020817
ZA 2004001073	A	20040826	ZA 2004-1073	20040210
NO 2004008011	A	20040519	NO 2004-811	20040224
BG 108598	A	20050331	BG 2004-108598	20040224
PRIORITY APPLN. INFO.:			DE 2001-10142734	A 20010831
			DE 2002-10223273	A 20020524
			WO 2002-EP9221	W 20020817

OTHER SOURCE(S): MARPAT 138:238169  
 GI



AB The invention relates to diaryl cycloalkyl derivs. and their physiol. compatible salts and physiol. functional derivs. The invention also relates to oxazoles I [Z = C3-8-alkyl, C3-8-alkenyl (rings may contain 1 or more oxygens); R1, R2, R4, R5 = H, F, Cl, Br, OH, NO2, CF3, OCF3, Cl-6-alkyl, O-(Cl-6-alkyl); R3 = H, Cl-6-alkyl; X, Y = Cl-6-alkyl (chains may contain 1 or more oxygens)] to their physiol. compatible salts and to a method for producing the same. Thus, (+)-cis-oxazole II was prepared from


cyclohexane-1,3-diol via O-alkylation with 4-(iodomethyl)-2-(4-fluorophenyl)oxazole, separation of cis/trans isomers, HPLC resolution of the cis isomers, and finally alkylation of the (-)-cis isomer with Me 2-(bromomethyl)-6-methylbenzoate. The compds. have lipid and/or triglyceride reducing properties and are suitable e.g. for treating lipid metabolic disorders, type II diabetes and syndrome X. The bioactivity of II was determined [EC50 = 0.3 nM vs. PPARα].

IT 501362-02-3P 501362-03-4P 501362-06-7P  
501362-09-0P 501362-12-5P 501362-15-8P  
501362-16-9P 501362-21-6P 501362-25-0P  
501362-26-1P 501362-27-2P 501362-28-3P  
501362-29-4P 501362-30-7P 501362-31-8P  
501362-32-9P 501362-33-0P 501362-34-1P  
501362-35-2P 501362-36-3P 501362-37-4P  
501362-38-5P 501362-39-6P 501362-43-2P  
501362-45-4P 501362-46-5P 501362-47-6P  
501362-48-7P 501362-49-8P 501362-50-1P  
501362-52-3P 501362-53-4P 501362-54-5P  
501362-55-6P 501362-58-9P 501362-59-0P  
501362-60-3P 501362-61-4P 501362-62-5P  
501362-65-8P 501362-67-0P 501362-70-5P  
501362-73-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation and PPAR activating activity of; preparation of oxazole diaryl

cycloalkyl derivs. and the use thereof as PPAR activators)  
RN 501362-02-3 CAPLUS  
CN Benzoic acid, 2-[[[1-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ox  
y]methyl-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-03-4 CAPLUS  
CN Benzoic acid, 2-[[[1-(1S,3R)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-06-7 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[1-(1S,3R)-3-[[2-(phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-09-0 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[1-(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-12-5 CAPLUS  
CN Benzoic acid, 2-[[[1-(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-15-8 CAPLUS  
CN Benzoic acid, 5-[[[1-(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-2-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-16-9 CAPLUS  
CN Benzoic acid, 2-[[[1-(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-21-6 CAPLUS  
CN Benzoic acid, 2-[[[1-(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.



RN 501362-25-0 CAPLUS  
CN Benzoic acid, 2-[[[1-(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)




RN 501362-26-1 CAPLUS  
CN Benzoic acid, 2-[[[1-(1R,3R)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)




RN 501362-27-2 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 501362-28-3 CAPLUS  
CN Benzoic acid, 2-[[[4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)



RN 501362-29-4 CAPLUS  
CN Benzoic acid, 2-[[[4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclopenten-1-yl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)




RN 501362-33-0 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)




RN 501362-34-1 CAPLUS  
CN Benzoic acid, 2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-35-2 CAPLUS  
CN Benzoic acid, 2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-30-7 CAPLUS  
CN Benzoic acid, 2-[[[5-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclooctyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)




RN 501362-31-8 CAPLUS  
CN Benzoic acid, 2-[[[1R,2R]-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclooctyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-32-9 CAPLUS  
CN Benzoic acid, 2-[[[1R,2S]-2-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]methyl]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-36-3 CAPLUS  
CN Benzoic acid, 2-[[[1R,3S]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 501362-37-4 CAPLUS  
CN Benzoic acid, 2-[[[trans-4-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]methoxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 501362-38-5 CAPLUS  
CN Benzoic acid, 2-[[[2-[[1R,3R]-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]ethyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




L8 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 501362-39-6 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.




RN 501362-43-2 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-45-4 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-46-5 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-47-6 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-(trifluoromethyl)phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)


L8 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501362-53-4 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(2,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-54-5 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(2-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-55-6 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-(trifluoromethoxy)phenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-58-9 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


L8 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501362-48-7 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)



RN 501362-49-8 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(4-chlorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-50-1 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(3-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-52-3 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3,4-dimethylphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)


L8 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 501362-59-0 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(3-cyanophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-60-3 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-phenyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)



RN 501362-61-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[3-[[5-methyl-2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)




RN 501362-62-5 CAPLUS  
CN Benzoic acid, 2-[[[3-[[2-(4-methoxyphenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)




RN 501362-65-8 CAPLUS  
CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-67-0 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[2-(4-methoxyphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-70-5 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-73-8 CAPLUS  
CN Benzoic acid, 2-[[[[(1S,3R)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 501362-14-7 CAPLUS  
CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



RN 501362-19-2 CAPLUS  
CN Benzoic acid, 5-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-2-methyl-, ethyl ester, rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.



RN 501362-20-5 CAPLUS  
CN Benzoic acid, 2-[[[[(1R,3S)-3-[[2-(4-fluorophenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-5-methyl-, ethyl ester, rel- (9CI)  
(CA INDEX NAME)


Relative stereochemistry.

Absolute stereochemistry.




IT 501362-01-2P 501362-08-9P 501362-11-4P  
501362-14-7P 501362-19-2P 501362-20-5P  
501362-42-1P 501362-69-2P 501362-72-7P  
501362-75-0P 501362-77-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and saponification of; preparation of oxazole diaryl cycloalkyl derivs. And the use thereof as PPAR activators)

RN 501362-01-2 CAPLUS  
CN Benzoic acid, 2-[[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 501362-08-9 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 501362-11-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[[(1S,3R)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 501362-42-1 CAPLUS  
CN Benzoic acid, 2-[[[[(1S,3R)-3-[[2-(4-bromophenyl)-5-methyl-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-6-methyl-, methyl ester (9CI)  
(CA INDEX NAME)




RN 501362-69-2 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 501362-72-7 CAPLUS  
CN Benzoic acid, 2-methyl-6-[[[[(1R,3S)-3-[[2-(4-methylphenyl)-4-oxazolyl]methoxy]cyclohexyl]oxy]methyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




AB This invention is directed to triaryl acid derivs. I and their salts, N-oxides, hydrates, solvates, and pharmaceutical compns. [wherein: Ar1, Ar2, Ar3 = aryl, fused arylcycloalkenyl, fused arylcycloalkyl, fused arylheterocyclyl, fused arylheterocyclyl, heteroaryl, fused heteroarylcyloalkenyl, fused heteroarylcyloalkyl, fused heteroarylheterocyclyl, or fused heteroarylheterocyclyl; A = bond, O, S, SO, SO2, CO, (un)substituted NH, NHCO, CONH, NHCNH, CH:N, etc.; B = bond, O, S, SO, SO2, C.tpbond.C, CO, (un)substituted NH, NHCO, or CONH; D = bond, O, S, C.tpbond.C, CO, (un)substituted NH, NHCO, or CONH; E = bond, CH2CH2; Z = (un)substituted CO2H, CHO, cyclo-imide, cyano, sulfonaminoacarbonyl, sulfonylamino, carbamoyl, tetrazolyl, etc.; R1, R5, R7, R9, R11 = H, halo, alkyl, CO2H, alkoxyacarbonyl, aralkyl; R2, R4, R6, R8, R10, R12 = (CH2)0-3X (where X = H or various substituents); n1 = 0-4; m1 = 0-4; n = 0-4; m = 0-5; p = 0-4; q = 0-6; with numerous provisos]. The compds. are PPAR receptor ligands, useful as agonists or antagonists thereof (no data). For instance, 2,6-dimethylbenzoic acid underwent a sequence of: (1) Me esterification, (2) benzylic bromination, (3) etherification with 3-(quinolin-2-ylmethoxy)phenol, and (4) alkaline hydrolysis with NaOH in aqueous EtOH, to give title compound II.

IT 303218-33-9P 303218-47-5P 303219-55-8P  
303219-57-0P 303219-59-2P 303220-12-4P  
303220-98-6P 303221-36-5P 303221-38-7P  
303221-40-1P 303221-44-5P 303221-87-6P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) [preparation of tri-aryl acid derivs. as PPAR receptor ligands]

RN 303218-33-9 CAPLUS


CN Benzoic acid, 2-methyl-6-[(3-{[2-(5-methyl-2-phenyl-4-oxazolvyl)ethoxy]vinyl}oxy]vinyl- (9CI) [CA INDEX NAME]




RN 303218-47-5 CAPLUS  
CN Benzoic acid,  
2-methyl-6-([3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl)-  
(9CI) (CA INDEX NAME)




RN 303219-55-8 CAPLUS  
CN Benzoic acid,  
2-[[3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]phenoxy]methyl  
]-6-methyl- (9CI) (CA INDEX NAME)




RN 303219-57-0 CAPLUS  
CN Benzoic acid,  
2-[[3-[(2-(3-fluorophenyl)-4-oxazolyl)methoxy]phenoxy]methyl  
]-6-methyl- (9CI) (CA INDEX NAME)




RN 303219-59-2 CAPLUS  
CN Benzoic acid, 2-[[3-[(2-(cyclohexyl-4-oxazolyl)methoxy]phenoxy]methyl]-6-  
methyl- (9CI) (CA INDEX NAME)




RN 303220-12-4 CAPLUS  
CN Benzoic acid, 2-methyl-6-([3-[(5-methyl-2-phenyl-4-  
oxazolyl)methoxy]phenoxy]methyl)- (9CI) (CA INDEX NAME)




RN 303220-98-6 CAPLUS  
CN Benzoic acid,  
2-methyl-6-([3-[(2-phenyl-4-oxazolyl)methoxy]phenoxy]methyl)-  
, methyl ester (9CI) (CA INDEX NAME)




RN 303221-36-5 CAPLUS  
CN Benzoic acid, 2-[[3-[(2-(cyclohexyl-4-oxazolyl)methoxy]phenoxy]methyl]-6-  
methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 303221-38-7 CAPLUS  
CN Benzoic acid,  
2-[[3-[(2-(3-fluorophenyl)-4-oxazolyl)methoxy]phenoxy]methyl  
]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)




RN 303221-40-1 CAPLUS  
CN Benzoic acid,  
2-[[3-[(2-(4-fluorophenyl)-4-oxazolyl)methoxy]phenoxy]methyl  
]-6-methyl-, methyl ester (9CI) (CA INDEX NAME)



RN 303221-44-5 CAPLUS  
CN Benzoic acid, 2-methyl-6-([3-[(5-methyl-2-phenyl-4-  
oxazolyl)methoxy]phenoxy]methyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 303221-87-6 CAPLUS  
CN Benzoic acid, 2-methyl-6-([3-[(2-(5-methyl-2-phenyl-4-  
oxazolyl)ethoxy]phenoxy]methyl)-, methyl ester (9CI) (CA INDEX NAME)




L8 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1994:54537 CAPLUS  
DOCUMENT NUMBER: 120:54537  
TITLE: Preparation of 4-(phenoxyalkyl)-2-oxazolines as acaricides and insecticides  
INVENTOR(S): Hirose, Taro; Kisada, Hiroshi; Saito, Shigeru; Fujimoto, Hiroaki  
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan  
SOURCE: Eur. Pat. Appl., 53 pp.  
CODEN: EPKXDW  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 553623	A1	19930804	EP 1993-100223	19930108
EP 553623	B1	20010404		
R: CH, DE, ES, FR, GB, IT, LI				
AU 9230491	A1	19930729	AU 1992-30491	19921231
AU 658955	B2	19950504		
ES 2155442	T3	20010516	ES 1993-100223	19930108
BR 9300299	A	19930803	BR 1993-299	19930127
JP 05271206	A2	19931019	JP 1993-11698	19930127
JP 3239508	B2	20011217		
US 5411979	A	19950502	US 1993-10015	19930127
PRIORITY APPLN. INFO.:			JP 1992-12967	A 19920128

OTHER SOURCE(S): MARPAT 120:54537  
GI



AB Title compds. [I: H, halo, (halo)alkyl, alkoxy, etc.; R2 = H, halo, alkyl, alkoxy, alkylthio; R3 = H, Me; R4 = (substituted) Ph; p = 1-4] were prepared  
Thus, 4-(Me3C)C6H4OH was condensed with BrCH2CH(OMe)2 and the product converted in 4 steps to 4-(Me3C)C6H4OCH2CH(NH2)CH2OH which was cyclocondensed with 2,6-F2C6H2COCl to give I (R1 = Me3, R2 = R3 = H, R4 = C6H3F2-2,6) which gave ≥90% control of Culex pipiens pallens larvae in H2O containing 3.5 ppm.  
IT 151856-99-4P  
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of, as acaricide and insecticide)  
RN 151856-99-4 CAPLUS  
CN Benzoic acid, 3-chloro-4-[4-[(2-(2,6-difluorophenyl)-4,5-dihydro-4-oxazolyl)methoxy]phenoxy]-, methyl ester (9CI) (CA INDEX NAME)


L8 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1973:45070 CAPLUS  
DOCUMENT NUMBER: 78:45070  
TITLE: Oxazole derivatives as fluorescent whiteners  
INVENTOR(S): Matsuo, Masatoshi; Sakaguchi, Tadao; Akamatsu, Takashi  
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd.  
SOURCE: Fr., 67 pp.  
CODEN: FRXXAK  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2066252		19710910		
DE 2050771			DE	
GB 1325550			GB	
JP 47030286		19720000	JP	
JP 47031924		19720000	JP	
JP 47032284		19720000	JP	
JP 48002305		19730000	JP	
JP 48002306		19730000	JP	
JP 48002307		19730000	JP	
JP 48002308		19730000	JP	
JP 48002309		19730000	JP	
JP 48002310		19730000	JP	
JP 48002311		19730000	JP	
JP 48002312		19730000	JP	
JP 48022304		19730000	JP	
JP 48032305		19730000	JP	
JP 48032306		19730000	JP	
JP 48032307		19730000	JP	
JP 48032308		19730000	JP	
JP 48032309		19730000	JP	
JP 48032310		19730000	JP	
JP 48032311		19730000	JP	
JP 48032312		19730000	JP	
JP 48032411		19730000	JP	
JP 48032566		19730000	JP	
JP 48037124		19730000	JP	
JP 48041116		19730000	JP	
JP 48041794		19730000	JP	
JP 49000432		19740000	JP	
JP 49000976		19740000	JP	
JP 49013952		19740000	JP	
JP 49014325		19740000	JP	
US 3843632		19740000	US	
PRIORITY APPLN. INFO.:			JP 1969-83990	19691021

AB Approx. 270 oxazole fluorescent whiteners of general structures I and II were prepared, where Q = p-C6H4CH:CH, p-C6H4CH:CHC6H4-p, p-C6H4C6H4-p, p-C6H4, CH:CH, C10H6, or a 5- or 6-membered heterocyclic group; R1, R2, R3, and R4 = lower alkyl, cyclohexyl, Ph or substituted Ph, or (R3R4) = benzo or naphtho; n = 0 or 1; and R5 = CH, Cl, CO2H, CO2Et, MeO, or carbamoyl.  
Thus, 4-ClCOC6H4CH:CHC6H4COCl-4 was condensed with MeCOCHMeNH2 and the product heated in H2SO4 to give fluorescent whitener III [31768-38-4].  
In another example, β-(benzoxazole-2-yl)acryloyl chloride was condensed with 4-ClC6H4COCH2NH2 followed by heating in polyphosphoric acid to give


L8 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L8 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)  
fluorescent whitener IV [38215-18-8]. Similarly prep. was fluorescent whitener II (R1 = R2 = Me, n = 0, R5 = 4- CONMe2) [31768-39-5].  
IT 40875-07-8P 40875-08-9P  
RL: IMF (Industrial manufacture); PREP (Preparation) (preparation of)  
RN 40875-07-8 CAPLUS  
CN Benzoic acid, 3-[2-[4-[2-(5-phenyl-2-oxazolyl)ethenyl]phenyl]ethenyl]-ethyl ester (9CI) (CA INDEX NAME)



RN 40875-08-9 CAPLUS  
CN Benzoic acid, 3-[2-[4-[2-(5-phenyl-2-oxazolyl)ethenyl]phenyl]ethenyl]-ethyl ester (9CI) (CA INDEX NAME)





=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

98.47

437.32

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-14.25

-14.25

STN INTERNATIONAL LOGOFF AT 08:07:26 ON 07 FEB 2006